Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699475 · ClinicalTrials.gov registry record · Phase 2
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
A Phase 2 study, sponsored by Bellicum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03699475 is a Phase 2 study that was terminated before completion, run by Bellicum Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT03699475, a Phase 2 study, was terminated before completion, sponsored by Bellicum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL rivogenlecleucel
- DRUG rimiducid
- PROCEDURE haplo-HSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2019-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699475
The ClinicalTrials.gov registry entry for NCT03699475 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03699475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03699475 about?
NCT03699475 is a clinical study titled "Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS". This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
What is the current status of trial NCT03699475?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-12-27. Estimated completion is 2019-07-23.
What interventions are being tested in trial NCT03699475?
The interventions under investigation include: Cyclophosphamide (DRUG), rivogenlecleucel (BIOLOGICAL), rimiducid (DRUG), haplo-HSCT (PROCEDURE).
Who is sponsoring clinical trial NCT03699475?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.